

Supplementary Appendix To:

Optimized testing strategy for the diagnosis of GAA-FGF14 ataxia

Authors

Céline Bonnet^{1,2*}; David Pellerin^{3,4*}; Virginie Roth¹; Guillemette Clément^{2,5}; Marion Wandzel¹; Laëtitia Lambert^{2,6}; Solène Frismand⁵; Marian Douarinou⁵; Anais Grosset⁵; Ines Bekkour⁵; Frédéric Weber¹; Florent Girardier¹; Clément Robin¹; Stéphanie Cacciatore¹; Myriam Bronner¹; Carine Pourié²; Natacha Dreumont²; Salomé Puisieux⁵; Marie-Josée Dicaire⁴; François Evoy⁷; Marie-France Rioux⁷; Armand Hocquel⁵; Roberta La Piana^{4,8}; Matthias Synofzik^{9,10}; Henry Houlden³; Matt C. Danzi¹¹; Stephan Zuchner¹¹; Bernard Brais^{4,12}; Mathilde Renaud^{2,5,6}

*Contributed equally to this work

Affiliations

¹ Laboratoire de Génétique, CHRU de Nancy, France

² INSERM-U1256 NGERE, Université de Lorraine, Nancy, France

³ Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, University College London, London, United Kingdom

⁴ Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, QC, Canada

⁵ Service de Neurologie, CHRU de Nancy, France

⁶ Service de Génétique Clinique, CHRU de Nancy, France

⁷ Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada

⁸ Department of Diagnostic Radiology, McGill University, Montreal, QC, Canada

⁹ Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany

¹⁰ German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

¹¹ Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA

¹² Department of Human Genetics, McGill University, Montreal, QC, Canada

Corresponding authors

Dr. Céline Bonnet

Laboratoire de génétique médicale, Hôpitaux de Brabois - CHRU de Nancy

Rue du Morvan, 54500 Vandoeuvre-lès-Nancy FRANCE

ce.bonnet@chru-nancy.fr

Dr. Mathilde Renaud


Service de génétique Clinique, Hôpitaux de Brabois - CHRU de Nancy

Rue du Morvan, 54500 Vandoeuvre-lès-Nancy FRANCE

m.renaud2@chru-nancy.fr

SUPPLEMENTARY FIGURES

Figure S1: Testing strategy for the diagnosis of *GAA-FGF14* ataxia




Normal alleles have (GAA)_{<250} repeats and expanded alleles have (GAA)_{≥250} repeats.

*Two expanded alleles are possible

Legend: N allele, normal allele <250 repeat units; LR-PCR, long-range polymerase chain reaction; MW, molecular weight.

Figure S2: *FGF14* allele size estimates by long-read nanopore sequencing and agarose gel electrophoresis.



(A) Passing-Bablok regression (blue line) with 95% confidence interval (shaded blue area) for allele size measured by nanopore sequencing and gel electrophoresis. The dashed black line show the identity line and the dashed red lines show the pathogenic threshold of $(GAA)_{\geq 250}$ repeats. (B) Bland-Altman plot shows the percentage difference between size estimates measured by targeted nanopore sequencing and gel electrophoresis as a function of the average of the two measurements for each sample. The dashed red lines show the mean bias between two techniques and the dashed gray lines show the limits of agreement, defined as the mean percentage difference $\pm 1.96SD$.

SUPPLEMENTARY TABLES

Table S1: Experimental conditions used for long-range PCR amplification and RP-PCRs

Long-range PCR protocols

Reagents	Primers	Cycling conditions
1. Phusion Flash High-Fidelity PCR Master Mix 2X (Thermo-Fisher)	LR-PCR F: TGCAAATGAAGGAAACTCTT R: CAATGATGAATTAAGCAGTTCC	98°C x 3 min [98°C x 10 sec 65°C x 15 sec – Each 2 cycles decreasing by 1°C 72°C x 3 min] x 12 cycles
2. Primers 1µM	fLR-PCR F: 6-FAM-TGCAAATGAAGGAAACTCTT R: CAATGATGAATTAAGCAGTTCC	[98°C x 10 sec 59°C x 15 sec 72°C x 3 min] x 20 cycles
3. gDNA 40ng		72°C x 5 min

RP-PCR protocols

Reagents	Primers	Cycling conditions
1. Phusion Flash High-Fidelity PCR Master Mix 2X (Thermo-Fisher)	3'RP-PCR F: TGCCCACATAGAGCTTAGTCT R: CACGACGTTGTAAAACGAC-GAAGAAGAAGAAGAAGAA M13-FAM: 6-FAM-CACGACGTTGTAAAACGAC	98°C x 3 min [98°C x 10 sec 65°C x 15 sec 72°C x 1 min] x 35 cycles
2. F primer 1µM	5'RP-PCR F: TGCAAATGAAGGAAACTCTT R: CACGACGTTGTAAAACGAC-TTCTTCTTCTTCTTCTTCTTC M13-FAM: 6-FAM-CACGACGTTGTAAAACGAC	72°C x 5 min
3. R primer 0.1µM		
4. M13-FAM 1µM		
5. gDNA 80ng		

F, forward; gDNA, genomic DNA; PCR, polymerase chain reaction; R, reverse

Table S2: Comparison of sizing estimates by fluorescent LR-PCR (with and without correction) and targeted nanopore sequencing.

Nanopore sizing repeat number [size bp]	fluorescent LR-PCR sizing				
	[size bp]	repeat number calculated		corrected	
258	876.90	242.30	-6%	266.02	3%
260	873.71	241.24	-7%	264.83	2%
261	879.92	243.31	-7%	267.14	2%
265	874.36	241.45	-9%	265.07	0%
271	900.00	250.00	-8%	274.63	1%
271	905.57	251.86	-7%	276.70	2%
280	921.94	257.31	-8%	282.81	1%
285	955.35	268.45	-6%	295.26	4%
285	929.72	259.91	-9%	285.71	0%
289	952.90	267.63	-7%	294.35	2%
295	936.54	262.18	-11%	288.25	-2%
300	1035.55	295.18	-2%	325.15	8%
305	1003.79	284.60	-7%	313.31	3%
323	1039.49	296.50	-8%	326.62	1%
325	1057.28	302.43	-7%	333.25	3%
332	1060.24	303.41	-9%	334.36	1%
338	1041.80	297.27	-12%	327.48	-3%
347	1062.12	304.04	-12%	335.06	-3%
350	1121.00	323.67	-8%	357.01	2%
363	1173.86	341.29	-6%	376.71	4%
371	1153.54	334.51	-10%	369.13	-1%
380	1215.20	355.07	-7%	392.12	3%
383	1208.65	352.88	-8%	389.68	2%
392	1228.55	359.52	-8%	397.09	1%
396	1220.51	356.84	-10%	394.10	0%
400	1214.87	354.96	-11%	392.00	-2%

Slope: 2.6827; y-intercept: 163.2416

Internal control: (GAA)₁₀ : 180,32 bp; (GAA)₂₅₈ :876.90 bp; (GAA)₃₂₃ :1039.69 bp; (GAA)₄₀₀ :1214.87 bp.

Table S3: Suggested items to be included in the report

Range: number of repeats	Reason for referral	
	Diagnostic testing	Carrier testing
Normal -Allele 1 <250 repeat units -Allele 2 <250 repeat units	The diagnosis of GAA- <i>FGF14</i> (SCA27B, late-onset) ataxia is excluded	Patient is not a carrier of a <i>FGF14</i> GAA repeat expansion
Non-GAA expansion: ≥250 repeat units -Allele 1 <250 repeat units -Allele 2 ≥250 non-GAA repeat units	The diagnosis of GAA- <i>FGF14</i> ataxia (SCA27B, late-onset) is excluded	-
GAA expansion: ≥250 repeat units -Allele 1 <250 repeat units -Allele 2 ≥250 GAA repeat units or -Allele 1 ≥250 GAA repeat units -Allele 2 ≥250 GAA repeat units	The diagnosis of GAA- <i>FGF14</i> ataxia (SCA27B, late-onset) is confirmed. The report should mention the indication of genetic counselling for the family of the patient (offering confirmatory carrier testing)	The patient is a carrier of a <i>FGF14</i> GAA repeat expansion